Company profile · Biotech & medical
UnicoCell Biomed
向榮生醫科技股份有限公司 · 6794
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
UnicoCell Biomed develops stem cell new drugs and cell therapies, focusing on regenerative medicine applications such as knee osteoarthritis and chronic kidney disease treatment.[1]
The company produces stem cell-derived technologies, exosomes, and patented ultra-low temperature biological specimen storage containers.[2]
It also provides one-stop CDMO services ranging from process development and GMP production to regulatory support.[3]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$1m | -44.4% | -48.7% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | −NT$4m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | UnicoCell Biomed Co., Ltd. |
|---|---|
| Chinese name | 向榮生醫科技股份有限公司 |
| Stock code | 6794 (TWSE) |
| Industry | Biotech & medical |
| Founded | 28 Mar 2018 |
| Listed | 21 May 2024 |
| Paid-in capital | NT$636m |
| Chairman | 蔡意文 |
| President | 洪懿珮 |
| Headquarters | 5 F., No. 13-20, Sec. 6, Minquan E. Rd., Neihu Dist., TAIPEI CITY 11494, TAIWAN (R.O.C.) |
| Website | https://www.unicocell.com |
| Official business description | 幹細胞新藥研發 · 幹細胞分泌物培養銷售 · 細胞檢測服務 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- MOPS 公司基本資料 向榮生醫科技股份有限公司 · mops · retrieved 04 Nov 2026
- 向榮簡介 - 向榮生醫科技股份有限公司 · website · retrieved 04 Nov 2026
- 產品及服務 - 向榮生醫科技股份有限公司 · website · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list